Associate, Life Sciences Investments
R1 CapitalCheck size: R1 Capital does not publish a standard person-specific check-size range on its current website.
Meghan Hoffman invests or supports investments through R1 Capital's published strategy: Back technically advantaged, capital-efficient companies in large scalable markets and support founders from proof of concept through growth using a national network and Rev1 partnership.
Technical advantage, capital efficiency, scalable markets and founders who can turn early traction into industry-defining companies.
No formal pass list is public. Businesses without technical differentiation, capital discipline or a large scalable market appear less aligned.
Show the technical moat, capital-efficient milestones, market scale, customer traction, team gaps and how R1 and Rev1 resources can accelerate the next critical stage.
No writing has been linked yet. Kit can search for posts, interviews, and fund essays worth reading before outreach.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Meghan Hoffman is a current Associate, Life Sciences Investments at R1 Capital, according to the firm's official roster. No additional background is inferred where the firm does not publish a biography.